Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
2Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Hoth Therapeutics, Inc. (HOTH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
4Distinct source URLs
12High confidence
0.874Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Hoth Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
H-C-WAINWRIGHT-CO-LLC
H-C-WAINWRIGHT-CO-LLC
92%
the Sales Agreement, dated November 8, 2024 by and between the Company and H.C. Wainwright & Co., LLC (the “Sales Agreement”)
VIRGINIA-COMMONWEALTH-UNIVERSITY-INTELLECTUAL-PR
VIRGINIA-COMMONWEALTH-UNIVERSITY-INTELLECTUAL-PR
92%
VCU granted Rocket One an exclusive, royalty-bearing license to certain patents
CHELEXA-BIOSCIENCES-INC
CHELEXA-BIOSCIENCES-INC
90%
During the three months ended March 31, 2026 and 2025, the Company recognized expenses of $ 0 and $ 625 , respectively, for license fees associated with the Assignment and Assumption Agreement by and…
MED30-LLC
MED30-LLC
90%
On January 13, 2025, the Company entered into a Patent Application Acquisition Agreement with Med30, LLC (the “Seller”), whereby the Seller sold, conveyed, assigned and transferred to the Company all…
NORTH-CAROLINA-STATE-UNIVERSITY
NORTH-CAROLINA-STATE-UNIVERSITY
90%
During the three months ended March 31, 2026 and 2025, the Company recorded expenses of $ 0 and $ 937 , respectively, for license fees associated with the license agreement by and between the Company…
THE-GEORGE-WASHINGTON-UNIVERSITY
THE-GEORGE-WASHINGTON-UNIVERSITY
90%
During the three months ended March 31, 2026 and 2025, the Company recorded expenses of $ 0 and $ 1,250 , respectively, related to license fees pursuant to the patent license agreement with The Georg…
UNIVERSITY-OF-CINCINNATI
UNIVERSITY-OF-CINCINNATI
90%
During the three months ended March 31, 2026 and 2025, the Company recognized expenses of $ 0 and $ 625 , respectively, for license fees associated with the Assignment and Assumption Agreement by and…
Hoth Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ZYL-THERAPEUTICS
ZYL-THERAPEUTICS
80%
In connection with the Company's March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 120,000 shares of Zylö Therapeutics
CO-LLC
CO-LLC
62%
ogether with such holder’s affiliates) would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares issuable…
Hoth Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
HOTH-DEBT-10049
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
HOTH-DEBT-10048
Warrants outstanding: 300000
90%
xbrl warrant detail from xbrl 2025-12-31.
HOTH-DEBT
Debt stack $5,678
90%
Market cache reports total debt of $5,678.
Hoth Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Hoth Therapeutics, Inc..
Hoth Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
HOTH-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC
Geode Capital Management, LLC
90%
13F overlay lists Geode Capital Management, LLC as top holder; 10 tracked holders.
Hoth Therapeutics, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
